Summary
Intensification of post-remission therapy in patients with de novo acute myeloid leukemia (AML) increases the rate of long-term remissions. The limitation is prolonged, severe myelosuppression with high morbidity and mortality. One potential option to overcome these complications is retransfusion of peripheral blood stem cells mobilized after previous cycles of induction or consolidation therapy. The AML CG has initiated a pilot study on the feasibility of autologous peripheral blood stem cell transplantation. Mobilization was performed after TAD consolidation and additionally after double induction chemotherapy in patients without leukemic blasts after the first course of induction. Eighty-seven patients have been enrolled with a median age of 44 years (18–63). 83 patients are currently evaluable. 69 patients (84%) achieved CR, 5 were nonresponders (6%), and 4 died early (10%). Peripheral blood stem cells were successfully collected in 29 of 39 patients after double induction (74%), in 12 of 30 patients after consolidation (40%) and in 3 of 7 patients (43%) after an additional therapy with cyclophosphamide. The median number of CD34 cells dropped significantly from 5.3 × 106/kg BW after double induction to 3.0 × 106/kg BW after TAD consolidation. This pilot study shows that mobilization of peripheral blood stem cells is possible in the majority of patients with de novo AML and can be incorporated in intensive chemotherapy protocols.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Büchner T, Hiddemann W, Wörmann B, Löffler H, Haferlach T, Gassmann W, Staib P, Heyll A, Aul C, Lengfelder E, Maschmeyer G, Ludwig W-D, Fonatsch C, Haase D, Schoch C, Sauerland C, Heinecke A: Intensified Therapy for AML: The Role of the HAM Combination. In: Acute Leukemias - Experimental Approaches and Novel Therapies. Eds: Hiddemann W, Büchner Th, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W. Springer Verlag. Haematology and Blood Transfusion 39, 821–823, 1998
Mayer RJ, Davis RB, Schiffer CA et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331: 896–903, 1994
Zittoun RA, Mandelli F, Willemze R, Dewitte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 322: 217, 1995
Harousseau JL, Cahn JY, Pignon B, Witz F, Milipied N, Delain M et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90:2978, 1997
Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K: Ramdomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 351: 700–708, 1998
Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Montastruc M: Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience. Nouv. Rev. Fr. Hematol. 35:17–19, 1993
Körbling M, Fliedner TM, Holle R, Magrin S, Baumann M, Holdermann E, Eberhardt K Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: Influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 7:343–349, 1991
Sanz MA, de la Rubia J, Sanz GF, Martin G, Martinez J, Jarque I, Sempere A, Gomis F, Senent L, Solder MA, et al.: Busulfan plus cyclophosphamide followed by autologous blood stem cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J. Clin. Oncol. 11:1661–1667, 1993
AML CG, unpublished data
Schiffer CA, Stone R, Moore J, Peterson B: Cancer and Leukemia Group B Studies with Hematopoietic Growth Factors in Patients with Acute Myeloid Leukemia. Haematology and Blood Transfusion 38: 461–464, 1997
Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term hemapoisis in cancer patients. Lancet 342:1134–1137, 1993
Campana D: Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of Minimal Residual Disease. Cytometry 18: 68–74, 1994
Wörmann B: Implications of detection of minimal residual disease. Current Opinions in Oncology 5:3–10, 1993
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wörmann, B. et al. (2000). Mobilization of Peripheral Blood Stem Cells after Intensive Induction and Consolidation Therapy in Adult Patients with De Novo AML. In: Berdel, W.E., et al. Transplantation in Hematology and Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59592-9_27
Download citation
DOI: https://doi.org/10.1007/978-3-642-59592-9_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64041-4
Online ISBN: 978-3-642-59592-9
eBook Packages: Springer Book Archive